Pi-Cardia today announced the first commercial procedures with its ShortCut leaflet modification device for enabling heart ...

Pi-Cardia Inc., a global leader in the development of leaflet modification solutions for treating heart valves, announced today the first commercial procedures with ShortCut™ - the world's first ...

Pi-Cardia Inc., a global leader in the development of leaflet modification solutions for treating heart valves, announced today the first commercial procedures with ShortCuttm - the world's first ...

First dedicated leaflet modification solution to enable TAVR in patients at risk of coronary obstruction Pi-Cardia Inc., a global leader in the development of leaflet modification solutions for treati ...

The Society for Cardiovascular Angiography & Interventions (SCAI) has published an expert consensus statement that provides ...

Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this year.

Edwards Lifesciences beat analysts' estimate for fourth-quarter profit on Tuesday, helped by strong demand for its artificial heart valves and other medical devices. Investors remain bullish on ...

In particular, research on Edwards' market-leading Sapien TAVR device suggests that the learning curve is 200 cases. That's the inflection point where the physician can deliver optimal patient ...

The supra-annular self-expanding Evolut PRO/PRO+/FX TAVR device was found to be superior for valve function and noninferior for clinical outcomes at one year compared to the balloon-expandable SAPIEN ...

A review highlights how, amid shifts in care delivery, US veterans can still find high quality at their VA medical center.

Advt The company's lead product, transcatheter aortic valve replacement (TAVR) device, is used for minimally invasive heart surgeries. Sales from the TAVR unit rose nearly 6per cent to $1.04 ...